# Intranasal (NAS) Ketamine for Cancer Pain

> **NCT03146806** · PHASE1,PHASE2 · COMPLETED · sponsor: **Emory University** · enrollment: 10 (actual)

## Conditions studied

- Cancer
- Pain

## Interventions

- **DRUG:** Intranasal ketamine

## Key facts

- **NCT ID:** NCT03146806
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-25
- **Primary completion:** 2020-04-22
- **Final completion:** 2020-04-22
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2021-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03146806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03146806, "Intranasal (NAS) Ketamine for Cancer Pain". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03146806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*